References
Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin 2001; 51: 15–36.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31.
Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284–90.
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938–46.
Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin 1995; 45: 50–62.
Goldberg RM, Fleming TR, Tangen CM, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 1998; 129: 27–35.
Jarnagin WR, Fong Y, KyA, Schwartz LH, Paty PB, Cohen AM, Blumgart LH. Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg 1999; 188: 33–42.
Girard P, Ducreux M, Baldeyrou P, et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996; 14: 2047–53.
Desch CE, Benson AB, Smith TJ, et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999; 17: 1312.
Sardi A, Nieroda CA, Siddiqi MA, Minton JP, Martin EW. Carcinoembryonic antigen directed multiple surgical procedures for recurrent colon cancer confined to the liver. Am Surg 1990; 56: 255–9.
Martin EW, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985; 202: 310–7.
Larson SM, Divgi CR, Scott AM. Overview of clinical radioimmunodetection of human tumors. Cancer 1994; 73: 832–5.
Larson SM, Divgi CR, Scott A, et al. Current status of radioimmunotherapy. Nucl Med Biol 1994; 21: 785–92.
Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol 1999; 26: 577–83.
Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23: 717–35.
Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999; 40: 1706–15.
Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 2000; 126: 549–59.
Moffat FL, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996; 14: 2295–305.
Stomper PC, D’Souza DJ, Bakshi SP, Rodriguez-Bigas M, Burke PA, Petrelli NJ. Detection of pelvic recurrence of colorectal carcinoma: prospective, blinded comparison of Tc-99m-IMMU-4 monoclonal antibody scanning and CT. Radiology 1995; 197; 688–92.
Patt YZ, Podoloff DA, Curley S, et al. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 1994; 12: 489–95.
Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235–8.
Jacobson M, Levkovitz R, Ben-Tal A, et al. Enhanced 3D PET OSEM reconstruction using inter-update Metz filtering. Phys Med Biol 2000; 45: 2417–39.
Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479–89.
Alexander HR Jr, Bartlett DL, Libutti SK. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am 1998; 4: 2–11.
Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6: 3062–70.
Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis [published erratum appears in Cancer 1998; 83: 2241]. Cancer 1998; 83: 1251–61.
Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129: 176–87.
Minton J, Chevinsky AH. CEA directed second-look surgery for colon and rectal cancer. Ann Chir Gynaecol 1989; 78: 32–7.
Minton JP. Technical surgical considerations for CEA directed second-look operations and hepatic tumor excision. Semin Surg Oncol 1991; 7: 143–5.
Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150–85.
Blomqvist L, Holm T, Goranson H, Jacobsson H, Ohlsen H, Larsson SA. MR imaging, CT and CEA scintigraphy in the diagnosis of local recurrence of rectal carcinoma. Acta Radiol 1996; 37: 779–84.
Buccheri G, Biggi A, Ferrigno D, et al. Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer. Thorax 1996; 51: 359–63.
Hughes K, Pinsky CM, Petrelli NJ, et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 1997; 226: 621–31.
Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582–9.
Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319–23.
Jarv V, Blomqvist L, Holm T, Ringertz H, Jacobsson H. Added value of CEA scintigraphy in the detection of recurrence of rectal carcinoma. Acta Radiol 2000; 41: 629–33.
Lechner P, Lind P, Binter G, Cesnik H. Anticarcinoembryonic antigen immunoscintigraphy with a 99mTc-Fab′ fragment (Immu 4) in primary and recurrent colorectal cancer. A prospective study. Dis Colon Rectum 1993; 36: 930–5.
Willkomm P, Bender H, Bangard M, Decker P, Grunwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000; 41: 1657–63.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Libutti, S.K., Alexander, H.R., Choyke, P. et al. A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels. Ann Surg Oncol 8, 779–786 (2001). https://doi.org/10.1007/s10434-001-0779-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0779-9